Genetic profiteering: scandal of firm 'hiding vital breast cancer data'
Company 'decided to withhold its trade secrets'
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Thursday 01 November 2012
The company that makes the world's biggest-selling gene test for breast and ovarian cancers is refusing to share groundbreaking knowledge that could benefit patients, academics claim.
Myriad Genetics is accused of deliberately withholding data that could help other scientists to understand cancer genetics, on the grounds that the information is commercially sensitive.
The healthcare company manufactures the test for determining whether women carry potentially lethal mutations of the two genes linked with inherited forms of breast and ovarian cancer. It has a monopoly on the tests in the United States and is about to start more aggressive marketing in Europe.
"We are very concerned that such important data is being withheld from those who need it," said Professor Martina Cornel, chair of the European Society of Human Genetics policy committee.
While Myriad is refusing to let other scientists have access to its data, the company has free access to the public databases compiled by other scientists, Professor Cornel said.
"Myriad's stated aim to enter the European market more vigorously may lead to unfair competition with academic institutions for predictive precision," she said.
"It is vital that progress towards personalised medicine, which holds out so much promise, is not hindered by companies maintaining private genomic databases."
In addition to testing for the cancer-causing mutations on the two BRCA genes, Myriad uses its tests to compile a database of other mutations known as "variants of unknown significance" (VUS) which it gathers from patients and their family members.
The company initially stopped sharing this information with other researchers in 2004 because of difficulties in matching data formats. However, in 2005 it adopted a deliberate policy of retaining the data as a trade secret, according to a study led by Robert Cook-Deegan of Duke University in North Carolina, a former member of the US Office of Technology Assessment.
Since then, Myriad has refused to share data on BRCA gene variants – which is normally done by placing the information in public databases – on the grounds that the data is proprietary information gathered as a result of its BRCA Analysis tests, on which it retains the patent rights.
"Current practices of proprietary databases may hinder interpretation of genomic data and impede the advance of personalised medicine," says the study, published in the European Journal of Human Genetics.
"Myriad clearly sees its proprietary database as a source of competitive advantage, one that will persist after its underlying patents expire or are invalidated in court," it adds.
Sharing the information on the VUS is important because it helps doctors correctly to interpret the results of a breast cancer test, the researchers said. Building up a database could be the reason why Myriad finds only 3 per cent of its tests fall in to the VUS unknown category, they said, while the tests in the hands of European testing services report a 20 per cent VUS rate, they said. Professor Cornel added: "Interpreting the variants of unknown significance that may be found on analysing the patient's genome plays an essential part in being able to provide proper counselling and if necessary preventative or therapeutic guidance.
"We know that, regrettably, medical geographic inequalities are common. But what is particularly worrying about this situation is that it is the first time that such inequalities have been based on a lack of access to clinical information, rather than lack of a product."
David Scott, director of science funding at Cancer Research UK, said that the charity has funded a wide spectrum of research into cancer genes, the results of which are publicly available to researchers around the world.
Dr Scott said: "The availability of large sets of data containing the identity and frequency of mutations in populations could help to speed up scientists' understanding of cancers and their risk factors – potentially enabling the development of new ways to diagnose and treat cancer in the future."
A spokesman for Myriad Genetics, which is based in Salt Lake City in the United States, was unavailable to comment.
Myriad Genetics: A history
Myriad Genetics has been at the centre of the controversy over gene patenting and the sometimes bitter squabble between public and private genomic science. Its founders include two professors, Mark Skolnick, 66, of Utah University, and Nobel laureate Walter Gilbert, 80, of Harvard University.
The search for the gene involved in inherited forms of breast cancer, which accounts for about 5 to 10 per cent of cases, was a competitive affair in the early 1990s, with teams on both sides of the Atlantic making important breakthroughs.
When Professor Skolnick identified and sequenced the gene, he and his company, Myriad, applied for patents and the control of royalties on any gene tests resulting from the discovery. Some scientists argued that Myriad could not have done it without the work of others who made their results public.
In the second quarter of 2012 alone, Myriad generated sales of over $105m (£65m) from its BRCA analysis test.
Ian McKellen and Patrick Stewart bromance continues: X-Men star gushes about 'pussy cat' BFF Patrick Stewart
David Cameron stung by jellyfish: PM hurt after ignoring advice of locals while on holiday
South Korea ferry: Vice principal rescued from sinking ship found hanged
Hollande's affair: Catherine Deneuve and Sophie Marceau in war of words over President's relationship with Julie Gayet
Kim Jong-un, crowds and contraband kit: Inside North Korea with the the Pyongyang marathon winner
The food poverty scandal that shames Britain: Nearly 1m people rely on handouts to eat – and benefit reforms may be to blame
US Navy christens huge $3 billion destroyer ship USS Zumwalt that appears as a fishing boat on enemy radar
Scottish independence: It is the English who should be on their knees, begging the Scots to vote ‘No’
Nigel Farage fatigue? Half of voters ‘immune’ to Ukip’s appeal
Nigel Farage: I’m taking on the status quo, and the Establishment’s fighting back
Refugee facing deportation from Sweden saved by fellow passengers refusing to let plane leave
- 1 KFC 'sorry' after lesbian couple are kicked out of Bath restaurant for 'heavy petting'
- 2 Dylan Tombides: West Ham confirm 20-year-old striker has died after battle with cancer
- 3 24 people applied for the 'world's toughest job', here are their interviews
- 4 'Sinful': Video of British Muslims dancing to Pharrell Williams's hit Happy comes under attack
- 5 PFA Player of the Year: Luis Suarez, Daniel Sturridge and Steven Gerrard all nominated as Liverpool dominate award shortlist
£150.00 per week: QA Apprenticeships: This company is a company that specializ...
£153.75 per week: QA Apprenticeships: This company is an innovative outsourcin...
£150.00 per week: QA Apprenticeships: This company has been providing on site ...
£150.00 per week: QA Apprenticeships: We've been supplying best of breed peopl...